Abstract
The impact of the cyclin dependent kinase (CDK) inhibitors p21Waf1 and p27Kip1 on paclitaxel-mediated cytotoxicity was investigated in RKO human colon adenocarcinoma cells with the ecdysone-inducible expression of p21Waf1 or p27Kip1. Ectopic expression of p27Kip1 arrested cells at G1 phase, whereas p21Waf1 expression arrested cells at G1 and G2. Expression of p21Waf1 after paclitaxel treatment produced much greater resistance to paclitaxel than did expression of p27Kip1. We attributed this difference to the additional block at G2 induced by p21Waf1, which prevented cells from entering M phase and becoming paclitaxel susceptible. Expression of p21Waf1 inhibited p34cdc2 activity and markedly reduced paclitaxel-mediated mitotic arrest, from 87.5 to 23%. In contrast, p27Kip1 expression also inhibited p34cdc2 but reduced mitotic arrest only slightly, from 87.4 to 74.5%. We concluded that the G2 block produced by p21Waf1, but not by p27Kip1, contributed to their unequal modulation of sensitivity to paclitaxel-mediated apoptosis in RKO cells, and there is no causal relationship between paclitaxel-mediated cytotoxicity and elevation of p34cdc2 activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- CDK:
-
cyclin-dependent kinase
- CDC2:
-
cell division control-2
References
Amato SF, Swart JM, Berg M, Wanebo HJ, Mehta SR and Chiles TC . 1998 Cancer Res 58: 241–247
Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L and Fojo T . 1997 Cancer Res 57: 130–135
Blagosklonny MV, Schulte T, Nguyen P, Trepel J and Neckers LM . 1996 Cancer Res 56: 1851–1854
Cayrol C, Knibiehler M and Ducommun B . 1998 Oncogene 16: 311–320
Donaldson KL, Goolsby GL, Kiener PA and Wahl AF . 1994 Cell Growth Differ 5: 1041–1050
Dulic V, Stein GH, Far DF and Reed SI . 1998 Mol Cell Biol 18: 546–557
Fan Z, Lu Y, Wu X, DeBlasio A, Koff A and Mendelsohn J . 1995 J Cell Biol 131: 235–242
Frankel A, Buckman R and Kerbel RS . 1997 Cancer Res 57: 2388–2393
Haldar S, Chintapalli J and Croce CM . 1996 Cancer Res 56: 1253–1255
Horwitz SB . 1992 Trends Pharmacol Sci 13: 134–136
Ibrado AM, Liu L and Bhalla K . 1997 Cancer Res 57: 1109–1115
Kapoor M and Lozano G . 1998 Proc Natl Acad Sci USA 95: 2834–2837
Larsen JK, Munch-Petersen B, Christiansen J and Jorgensen K . 1986 Cytometry 7: 54–63
Lee LF, Li G, Templeton DJ and Ting JP . 1998 J Biol Chem 273: 28253–28260
Li W, Fan J, Banerjee D and Bertino JR . 1999 Mol Pharmacol 55: 1088–1093
Ling YH, Tornos C and Perez-Soler R . 1998 J Biol Chem 273: 18984–18991
Medema RH, Klompmaker R, Smits VA and Rijksen G . 1998 Oncogene 16: 431–441
Niculescu AB, Chen X, Smeets M, Hengst L, Prives C and Reed SI . 1998 Mol Cell Biol 18: 629–643
Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A . 1994 Genes Dev 8: 9–22
Rakovitch E, Mellado W, Hall EJ, Pandita TK, Sawant S and Geard CR . 1999 Int J Radiat Oncol Biol Phys 44: 1119–1124
Rowinsky EK . 1997 Semin Oncol 24Suppl 19: 1–12
Schiff PB and Horwitz SB . 1980 Proc Natl Acad Sci USA 77: 1561–1565
Shen SC, Huang TS, Jee SH and Kuo ML . 1998 Cell Growth Differ 9: 23–29
Sorger PK, Dobles M, Tournebize R and Hyman AA . 1997 Curr Opin Cell Biol 9: 807–814
Strobel T, Swanson L, Korsmeyer S and Cannistra SA . 1996 Proc Natl Acad Sci USA 93: 14094–14099
Sumantran VN, Ealovega MW, Nunez G, Clarke MF and Wicha MS . 1995 Cancer Res 55: 2507–2510
Toyoshima H and Hunter T . 1994 Cell 78: 67–74
Uren A, Jakus J, de MF, Yeudall A, Santos E, Gutkind S and Heidaran MA . 1997 J Biol Chem 272: 21669–21672
van Bree C, van der Maat B, Ceha HM, Franken NA, Haveman J and Bakker PJ . 1999 J Cancer Res Clin Oncol 125: 549–555
Verlhac MH, de Pennart H, Maro B, Cobb MH and Clarke HJ . 1993 Dev Biol 158: 330–340
Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T and Wimalasena J . 1998 J Biol Chem 273: 4928–4936
Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A and Mendelsohn J . 1996 Oncogene 12: 1397–1403
Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ and Hung MC . 1998 Mol Cell 2: 581–591
Acknowledgements
The authors wish to thank Mr J Parant and Dr G Lozano for providing RKO-pVgRXR cell clone, Mrs K Ramirez and Dr NT Van for technical assistance with flow cytometry analyses, and Mr M Worley for editorial assistance with the manuscript. This work was supported by the NIH grant CA68425, the Cancer Center core grant CA16672, and an MD Anderson Cancer Center Start-up fund (to Z Fan). M Schmidt was supported by a fellowship from the Ernst Schering Research Foundation, Berlin, Germany.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmidt, M., Lu, Y., Liu, B. et al. Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1. Oncogene 19, 2423–2429 (2000). https://doi.org/10.1038/sj.onc.1203546
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203546
Keywords
This article is cited by
-
The p53/p73 - p21CIP1 tumor suppressor axis guards against chromosomal instability by restraining CDK1 in human cancer cells
Oncogene (2021)
-
Loss of KLF14 triggers centrosome amplification and tumorigenesis
Nature Communications (2015)
-
Synthesis of new Benzo[f]isoindole-4,9-diones as anticancer compounds
Monatshefte für Chemie - Chemical Monthly (2010)
-
TACC3 depletion sensitizes to paclitaxel-induced cell death and overrides p21WAF-mediated cell cycle arrest
Oncogene (2008)
-
Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis
Oncogene (2008)